Skip to content
S6043Senate2021-2022 SessionSame asA3405

Warn Patients on Pain Meds

Official title

“Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications”

Sponsor Pete HarckhamSD-40Affects Health
Status
In Senate Committee
Health
Impact
5/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill requires health practitioners to discuss opioid risks with patients before prescribing and mandates counseling on overdose risks and opioid antagonist availability.

Why it matters

  1. Enhances patient awareness of opioid dangers. By mandating explicit conversations about addiction, overdose, and drug interactions, the bill aims to ensure that patients (and guardians for minors) fully understand the serious risks before starting or continuing opioid therapy.

  2. Promotes safer prescribing practices. The requirement for repeated discussions before initial and third prescriptions encourages practitioners to regularly reassess the necessity and appropriateness of opioid use, potentially reducing unnecessary or prolonged exposure.

  3. Increases access to life-saving interventions. By requiring prescribers to inform patients about opioid antagonists like naloxone, the bill improves the likelihood that patients and families will have access to tools that can reverse overdoses, potentially saving lives.

  4. Standardizes provider guidance. Directing the health department to develop discussion guidelines helps ensure that all practitioners follow consistent, evidence-based protocols, reducing variability in how opioid risks are communicated.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Warn Patients on Pain Meds

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Pete Harckham

Senator · Senate District 40

Chair, Alcoholism And Substance Abuse

No co-sponsors yet.

History

  1. Referred to health
  2. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A3405Assembly

Explain Opioid Risks Before Prescribing

In Assembly Committee · Health · Sponsor Linda Rosenthal

Impact 6 · Moderate0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

6043

2021-2022 Regular Sessions

IN SENATE

March 31, 2021

Introduced by Sen. HARCKHAM -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to requiring health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; and in relation to opioid analgesic prescriptions

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The public health law is amended by adding a new section 3309-b to read as follows:

§ 3309-b. Practitioner and patient discussions; opioid prescriptions. 1. Prior to issuing the initial prescription of a Schedule II controlled substance for the treatment of pain or any other opioid drug which is a prescription drug for acute or chronic pain and again prior to issuing the third prescription of the course of treatment, a practitioner shall discuss with the patient, or the patient's parent or guardian if the patient is under eighteen years of age and is not an emancipated minor, the risks associated with the drugs being prescribed, including but not limited to:

(a) the risks of addiction and overdose associated with opioid drugs and the dangers of taking opioid drugs with alcohol, benzodiazepines and other central nervous system depressants;

(b) the reasons why the prescription is necessary;

(c) alternative treatments that may be available; and

(d) the risks associated with the use of the drugs being prescribed, specifically that opioids are highly addictive, even when taken as prescribed, that there is a risk of developing a physical or psychological dependence on the controlled substance, and that the risks of taking more opioids than prescribed, or mixing sedatives, benzodiazepines or alcohol with opioids, can result in fatal respiratory depression.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00932-01-1

S. 6043 2

2. The department shall develop and make available to practitioners guidelines for the discussion required by this section.

§ 2. The public health law is amended by adding a new section 3309-c to read as follows:

§ 3309-c. Opioid analgesic prescription. 1. For the first opioid analgesic prescription of a calendar year that is greater than a one week's supply, the prescribing physician shall counsel the patient on the risks of overdose, and inform the patient of the availability of an opioid antagonist, including, but not limited to, naloxone.

2. For the purposes of this section, the following terms shall have the following meanings:

(a) "Opioid analgesics" means the medicines buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene as well as their brand names, isomers and combinations.

(b) "Opioid antagonist" means an FDA-approved drug that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body. The opioid antagonist is limited to naloxone or other medications approved by the department for this purpose.

§ 3. This act shall take effect on the one hundred twentieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to requiring health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; and in relation to opioid analgesic prescriptions

Purpose

Amends the public health law to better protect the health and safety of patients undergoing opioid or related schedule II controlled substance prescription dosage for treatment as well as inform patients of the side-effects that may result from such use.

Summary of provisions

Section 1 amends the public health law by adding a new section3309-b.

Section 2 amends the public health law by adding a new section3309-c.

Section 3 provides the effective date.

Justification

When patients receive opioid and other schedule II controlled substance prescriptions for pain relief, they are often uninformed of the risks and side-effects associated with the use of aforesaid medications such as; physical and psychological dependencies and abuse. Moreover, patients are frequently neglected to be provided with information of alternative prescriptions available to them, or why the prescription is necessary to their well-being. This legislation will help in preventing patients from being left in the dark regarding the risk management, side effects, alternative methods, and imperatives of their prescribed medi- cation.

Legislative history

2019-20: S4277 referred to Health; same as A7285 (Rosenthal L) referred to health;

Fiscal implications

None to the State.

Effective date

On the sixteenth day after it shall become law.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.